Treatment of Neuroendocrine Tumors
Study name: A Randomized, Double-Blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (CABINET)
Description: Researchers at the WL Nugent Cancer Center are conducting a Phase III clinical trial to determine if the chemotherapy medication cabozantinib is effective for treating neuroendocrine tumors (cancer in neuroendocrine cells that can occur anywhere in the body).
Cabozantinib is currently approved by the FDA for treating thyroid and kidney cancer. This study is to determine if it is also effective on neuroendocrine tumors as compared to placebo.
- Group 1 (study group): Receive chemotherapy treatment with cabozantinib.
- Group 2 (control group): Receive a placebo.
Who can participate?
This study is open to men and women age 18 and over who are diagnosed with neuroendocrine cancer and have any of the following conditions:
- Tumor is located in the pancreas or other area of the body where it cannot be removed by surgery (inoperable)
- Cancer has spread
- Cancer has been treated in the past with the generic drug everolimus
What to expect
-
You will meet with your doctor to discuss what is involved in the study and the possible benefits and risks. If you and your doctor agree this clinical trial is right for you, you will be asked to sign a consent form.
-
This is a randomized study, where you will be assigned by chance to one of the treatment groups listed above.
-
You will periodically complete questionnaires about your condition, side-effects from treatment, etc.
-
Blood samples may be collected before, during, and after treatment for study analysis.
Please talk with your doctor about whether this clinical trial is right for you.